A phase I study of sequential vinorelbine followed by paclitaxel

Annals of Oncology

Volumn 10, Issue 7, 1999, Pages 861-863

  Budman, D R ^a,c   Weiselberg, L ^a   O'Mara, V ^a   Buchbinder, A ^a   Lichtman, S M ^a   Donahue, L ^a   Adams, L M ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Breast cancer; Paclitaxel; Phase I; Vinorelbine

Indexed keywords

NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE WEAKNESS; MYALGIA; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032766022     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008351915582     Document Type: Article

References (12)

1. Budman DR. Vinorelbine (Navelbine): A third-generation vinca alkaloid. Cancer Invest 1997; 15: 475-90.
2. Adams DJ. Synergy of navelbine-taxol combination treatment in two human breast cancer cell lines. Proc Am Assoc Cancer Res 1994; 35: 1944a.
3. Knick VC, Eberwein DJ, Miller CG. Vinorelbine tartrate and paclitaxel combinations: Enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 1995; 87: 1072-7.
4. Budman DR, Calabro A, Stiel L et al. In vitro studies of paclitaxel in combination with either etoposide or vinorelbine: Sequence dependent effects causing synergism or antagonism. Proc Am Assoc Cancer Res 1996; 37: 2493a.
5. Havlin K, Lucas S, Guaspari A et al. Phase I/II study of daily × 3 navelbine with an attempt at dose-escalation with filgrastim in metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 1996; 15: 154a.
6. Khayat D, Covelli A, Variol P et al. Phase I and pharmacologic study of intravenous (i.v.) vinorelbine (VRL) in patients (PTS) with solid tumors. Proc Am Soc Clin One 1995; 14: 469a.
7. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs 1992; 10: 239-53.
8. Parimoo D, Jeffers S, Muggia FM. Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst 1996; 88: 1079-80.
9. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17:1061-70.
10. Dieras V, Fumoleau P, Bourgeois H et al. Taxoids in combination chemotherapy for metastatic breast cancer. Anti-Cancer Drugs 1996; 7: 47-52.
11. Ibrahim N, Hortobagyi GN, Valero V et al. Phase I study of vinorelbine (NVB; navelbine) and paclitaxel (PTX) by simultaneous (sim) 3-hr infusion (inf) for untreated metastatic breast cancer (MBC). Proc Am Assoc Cancer Res 1995; 36: 1443a.
12. Acuna LR, Langhi M, Perez J et al. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 1999; 17: 74-81.